Introduction
The generation of mice with genetically determined deficiencies of the natural killer cell lineage in addition to the B-and T-cell lineages has made it possible to create efficient and reproducible xenotransplant models to investigate the properties and biology of primitive human hematopoietic cells. The most widely used host strain for such studies has been the nonobese diabetic severe combined immunodeficiency (NOD/SCID) mouse, 1 generated by backcrossing a defective scid gene onto the NOD background. 2 Previous studies showed that repeated intraperitoneal injections of mg quantities of human interleukin-3 (IL-3), granulocyte/macrophage-stimulating factor (GM-CSF), Steel factor (SF) and erythropoietin (Epo) into NOD/SCID mice already engrafted with human cord blood or adult bone marrow (BM) cells enhanced the output of cells at all levels of differentiation. These included progenitors detected in vitro as colony-forming cells (CFCs) and long-term culture-initiating cells (LTC-ICs) as well as cells able to regenerate human lymphoid and myeloid cells in secondary NOD/SCID mice. 3, 4 In engrafted mice, human G-CSF administration with or without human SF was shown to cause human progenitor mobilization. 5 In addition, it was reported that in vivo administration of these growth factors at the time of transplantation can enhance the 'take' of small numbers of purified CD34
þ cord blood cells 6 as can also be achieved by a brief treatment of the cells either in vivo 4 or ex vivo 7 just prior to their transplantation. In humans, a variety of neoplastic disorders including acute myeloid leukemia 8 and chronic myeloid leukemia (CML) 9 have been associated with an inappropriate expression of IL-3, GM-CSF and G-CSF by the malignant progenitors. This confers on these cells an autocrine growth potential in vitro and, in vivo, they appear to be mobilized. Other conditions associated with chronic inflammatory reactions, for example, sickle cell disease (SCD) are also characterized by a continuously increased level of human hematopoietic growth factors in the serum, 10, 11 and the primitive cells in SCD patients also appear to be mobilized. 12, 13 No studies to date have revealed evidence of any deleterious quantitative or functional hematopoietic changes as a consequence of continuous exposure to elevated levels of human IL-3, GM-CSF or SF in vivo. Nevertheless, the finding that exposure of very primitive hematopoietic cells to excessive concentrations of IL-3 in vitro promotes their differentiation at the expense of their self-renewal 14, 15 predicts that this could have similar consequences in vivo.
Repeated injection of growth factors results in multiple shortlived pulses of high levels of growth factors in the circulation and presumably in the BM. To develop a more convenient and possibly more 'physiologic' xenotransplant model of continuous high-level exposure to human-specific hematopoietic growth factors, we developed a mouse expressing transgenic cDNAs encoding human IL-3, GM-CSF and SF, and then backcrossed this mouse onto a NOD/SCID background. 16 Here, we report the perturbations of human hematopoiesis that occur when these 'NOD/SCID-3/GM/SF' mice are transplanted with normal human adult BM or fetal liver cells. The results provide evidence not only that terminal human granulopoiesis and mobilization of progenitors can be enhanced in this model but also that this is accompanied by a variable decrease in human erythropoiesis and a very pronounced reduction in the regeneration of more primitive human hematopoietic cells, including those capable of repopulating secondary NOD/SCID mice.
Materials and methods

Human cells
Cryopreserved normal human cadaveric marrow obtained from the Northwest Tissue Center (Seattle, WA, USA) was used as a source of normal BM cells. Human fetal livers were obtained from 11-to 19-week-old aborted human fetuses. In both cases, access to the cells was obtained according to approved institutional procedures. Single-cell suspensions were prepared from the fetal liver samples either by pushing tissue fragments through a coarse sieve or by enzymatic dispersion (Dispase II, 2.4 u/ml (Boehringer Mannheim, Laval, PQ, Canada) in PBS 1Â (StemCell Technologies, Vancouver, BC, Canada), followed by trituration in EGTA/EDTA dissociation buffer (GIBCO-BRL, Burlington, ON, Canada) as described. 17 Low-density (o1.077 g/cm 3 ) cells were isolated by centrifugation of the cells on Ficoll-Hypaque (Pharmacia Biotech AB, Uppsala, Sweden), and these were then washed twice in Hanks' balanced salt solution supplemented with 5% fetal calf serum (FCS, StemCell Technologies) (HF). Mice were injected either directly with lowdensity cells or after the immunomagnetic removal of lineage marker-positive (lin þ ) cells on a column (StemSept, StemCell Technologies) according to the manufacturer's instructions.
Animals
Individual plasmid-based expression cassettes for human IL-3, human GM-CSF and human SF-were generated, in which the respective growth factor cDNA was placed under the control of a human cytomegalovirus promoter/enhancer sequence and linked to a human growth hormone intronic and polyadenylation sequence (details available on request). To generate human IL-3, human GM-CSF and human SF-producing NOD/SCID mice, expression cassettes for each growth factor were isolated free of plasmid backbone, mixed and microinjected into C57BL/ 6xC3H/HeN fertilized eggs. A mouse displaying ng/ml levels of all three growth factors in its serum as assessed by standard ELISA measurements using kits from R & D (Minneapolis, MN, USA) was then selected and used to derive progeny with the same phenotype. These were then repeatedly backcrossed first onto Balb/c-scid/scid mice (selecting at each generation both for retention of all three human transgenes by serum ELISA assays and the presence of the scid/scid genotype, as assessed by the detection of an absence of circulating B and T cells) and then onto NOD/LtSz-scid/scid (NOD/SCID) mice for at least 11 generations (again selecting for retention of the three human transgenes at each generation). The levels of human IL-3, GM-CSF and SF in the serum of transgenic mice used in the present experiments were 1.570.5 ng/ml IL-3, 3.870.5 ng/ml GM-CSF and 2.070.5 ng/ml SF. All mice were bred and maintained in microisolators under controlled sterile conditions. Mice (6 to 8 weeks old) were sublethally irradiated with 350 cGy from a 137 Cs source less than 24 h prior to being injected intravenously with human cells. Irradiated mice were given sterile water supplemented with 2.5 mg/ml ciprofloxacin (Bayer Inc., Etobicoke, ON, Canada) three times per week. To assess the numbers and types of human cells produced, mice were killed at the times indicated and the BM, spleen and blood cells collected and suspended in cold HF supplemented with 5% pooled normal human serum (HF/5% HS) as described previously. 3 In some experiments, the transplanted mice were given six intraperitoneal injections of 10 U of human Epo (StemCell Technologies) spread over a 2-week interval 3 days prior to being killed.
Flow cytometry
Cells to be analyzed were incubated for 10 min at 41C with HF/5% HS and with 3 mg/ml 2.4G2 anti-mouse Fc receptor antibody (American Type Culture Collection, Rockville, MD, USA) to avoid nonspecific binding of the test antibodies. Separate aliquots of cells were then incubated for 30 min at 41C with the following combinations of antibodies against human antigens: (1) anti-human CD34-FITC (8G12) plus anti-CD19-PE and anti-CD20-PE (both from Becton Dickinson, San Jose, CA, USA); (2) anti-CD71-PE (OKT-9) plus anti-CD45-PE, anti-CD15-FITC and anti-CD66b-FITC (all from Pharmingen, Mississauga, ON, Canada); (3) antiglycophorin-A-FITC (10F7); (4) anti-CD41 (3H2); (5) anti-CD34-FITC and anti-CD38-PE (Becton Dickinson); (6) anti-Gr-1-biotin (8C5); (7) anti-Mac-1-biotin (M1/70); and (8) anti-Ter 119-PE (Pharmingen). Cells were then washed twice with HF, the second wash containing 1 mg/ml propidium iodide (PI, Sigma Chemical Co., St Louis, MO, USA). The acquisition and analysis of the cells were performed on a FACSort using LYSIS II or Cell Quest software (Becton Dickinson). Positive cells were defined as those exhibiting a level of fluorescence that exceeded 99.98% of that obtained with irrelevant isotypematched control antibodies labeled with the same fluorochromes. To calculate the total number of a given type of human cells in the entire mouse BM, the number determined to be present in the two femurs and two tibiae was multiplied by four based on the assumption that the cells present in these four bones constitute approximately 25% of the total mouse BM mass. 18 In vitro assays CFC and LTC-IC assays were performed as described previously. 3, 19 Briefly, for CFC assays, FACS-sorted human CD45 þ CD34 þ cells were cultured in methylcellulose medium (H4330, StemCell Technologies) supplemented with 50 ng/ml human SF (purified from human SF cDNA-transfected Cos cell supernatants in the Terry Fox Laboratory) and 20 ng/ml each of human IL-3 (Novartis, Basel, Switzerland), IL-6 (Cangene, Mississauga, ON, Canada), GM-CSF (Novartis), G-CSF (StemCell Technologies) and 3 u/ml Epo. To detect human CFCs in unseparated suspensions of cells from transplanted mice, RBCs were lysed with ammonium chloride (StemCell Technologies) and then plated in methylcellulose medium (H4100, StemCell Technologies) supplemented with 15% FCS, 10% human serum, 20 ng/ml human IL-3 and human G-CSF plus 50 ng/ml human SF to achieve the exclusive stimulation of human CFCs. 3 Murine CFC assays were performed by culturing cell suspensions in methylcellulose medium designed to maximize the growth of murine colonies (M3434, StemCell Technologies). Human CD34 þ cells were assayed for LTC-ICs by culturing them on pre-established irradiated murine fibroblasts genetically engineered to produce human IL-3, G-CSF and SF, and then determining the number of CFCs present 6 weeks later. The number of LTC-ICs present in the input (human fetal liverderived) inocula was calculated by dividing the total number of CFCs present in the 6-week-old cultures by 72. 20 
Statistical analysis
Differences between groups were evaluated using the Student's t-test. The frequency of human lymphomyeloid repopulating cells was determined from the proportion of negative recipients measured in groups of NOD/SCID mice injected with different numbers of test cells using L-calc software (StemCell Technologies) that employs Poisson's statistics and the method of maximum likelihood. 21 
Results
NOD/SCID mice genetically engineered to produce human IL-3, GM-CSF and SF have mobilized progenitors and increased splenic hematopoiesis
We first sought to determine whether there was any effect of constitutively produced human IL-3, GM-CSF and SF on the endogenous hematopoiesis in mice to be used as test hosts of human hematopoietic cell transplants, in spite of the reported lack of (or poor) reactivity of these growth factors with murine receptors.
22,23 Table 1 shows a comparison of the cells present in the BM, spleen and blood of untreated adult growth factor (human IL-3, GM-CSF and SF) -producing and parental (control) NOD/SCID mice. In the BM of the NOD/SCID-3/GM/SF mice, the number of myeloid (Gr-1 þ /Mac-1 þ ) cells and CFCs (primarily CFU-GMs) were modestly increased (1.5-to two-fold) and the number of erythroid (Ter119 þ ) cells was correspondingly decreased, although only the latter effect reached statistical significance (Po0.05). In contrast, both erythropoiesis and myelopoiesis were enhanced in the spleen (Po0.05) and this was accompanied by a marked (410-fold), albeit highly variable, increase in splenic CFCs. In the peripheral blood, the only consistent change seen was in the number of circulating CFCs that were elevated in the transgenic mice B4-fold (Po0.05). Taken together, these results suggest that the levels of human IL-3, GM-CSF and SF produced in the transgenic mice (on average B2-4 ng/ml in the serum) were able to cause a significant perturbation in the numbers of terminally differentiating murine cells in the BM associated with a mobilization of their more primitive progenitors (CFCs) into the blood and their accumulation and activation in the spleen. Nevertheless, these changes were compensated terminally as the final cellularity of the BM, spleen and numbers of WBCs in the blood of the two NOD/SCID genotypes were not different ( Table 1) .
Evidence of human progenitor mobilization in NOD/ SCID-3/GM/SF mice engrafted with human BM cells
We then assessed the effect of constitutively elevated levels of human IL-3, GM-CSF and SF on the number and distribution of human hematopoietic cells produced in irradiated NOD/SCID mice transplanted with normal adult human BM cells. Groups of irradiated mice were injected with 4.4-6.6 Â 10 6 low-density lin À cells (on average, 35% CD34 þ ) each and the mice were then killed 6 weeks later for analysis. The total number of human hematopoietic (CD45/71 þ ) cells present in the BM of the growth factor-producing mice was found to be significantly elevated (574-fold, Po0.05) in comparison to the regular NOD/SCID recipients of the same cells, although the numbers of human CFCs in the BM of both types of mice were the same (Figure 1 ). Higher numbers of human CFCs were, however, detected in the blood (and the spleen) of the NOD/SCID-3/GM/ SF mice, although only the difference in blood values was significant (Po0.05). These findings indicate that the human growth factors produced in the NOD/SCID-3/GM/SF mice were also sufficient to stimulate human hematopoiesis in the BM and likely at a stage even prior to the generation of human CFCs, since their numbers were sustained in the BM in spite of their continuous increased mobilization into the blood.
As we had previously shown that repeated injections of human IL-3, GM-CSF and SF plus Epo could markedly stimulate terminal human erythropoiesis in similarly engrafted NOD/SCID mice, 20 it was of interest to determine whether this effect would be mimicked in NOD/SCID-3/GM/SF mice given injections of human Epo (only). Therefore, a group of 12 NOD/SCID-3/GM/ SF mice were transplanted with adult human BM cells and then half of these were given six intraperitoneal injections of human Epo between days 15 and 30 post-transplant (at 2-to 3-day intervals, 10 U/injection). The mice were then killed and analyzed 3 days after the last injection. As shown in Table 2 , the Epo injections appeared to have no effect on the low numbers of terminally differentiating human erythroid (glycophorin A þ ) cells present in the BM. In fact, although the results in individual mice in each group were quite variable, on average, the number of more primitive human erythroid cells (CFU-E/BFU-Es) in the BM of the Epo-injected mice was markedly reduced. Moreover, this decrease in the human cells present also extended to the primitive granulopoietic cells and to both the predominant human B-lineage cells and the less Values shown are the mean7s.e.m. of the number of murine cells of each type indicated per organ (BM and spleen) or per ml (blood). BM values were calculated as described in the Materials and methods section assuming two femurs and two tibiae represent 25% of the total BM. 18 Data are from three mice of each genotype analyzed individually. Total refers to total nucleated cells. *Indicates that the value is significantly different from that obtained for NOD/SCID hosts (Po0.05).
Figure 1
Altered numbers of human CFCs in the BM, spleen and blood of NOD/SCID-3/GM/SF mice. Regular (open bars) and human growth factor-producing NOD/SCID mice (black bars) were transplanted with 2.6-6.2 Â 10 6 low-density lin À cells from normal adult human BM and then killed 6 weeks later for assessment. Values shown are the mean7s.e.m of 18 NOD/SCID mice and 14 NOD/SCID-3/ GM/SF mice analyzed individually and are expressed as the number of cells per organ (BM and spleen) or per ml (blood), assuming two femurs and two tibiae represent 25% of the total BM. 18 Only the difference between the human CFC numbers in the blood of the two types of hosts is significant (Po0.05).
prominent terminally differentiating human granulopoietic and megakaryopoietic cells.
NOD/SCID-3/GM/SF mice show reduced regeneration of very primitive hematopoietic cells with the laterselective amplification of human myelopoiesis
To investigate the effects of constitutively elevated levels of circulating human IL-3, GM-CSF and SF on the generation/ maintenance of earlier subsets of human hematopoietic cells, parental and transgenic NOD/SCID mice were transplanted with human fetal liver cells since these are known to regenerate much larger numbers of the most primitive subsets of human hematopoietic cells than their counterparts in either adult BM or even cord blood.
20,24 Table 3 shows a comparison of the numbers and types of human cells measured in the BM of the two types of host 6 weeks after the transplantation of 1.1-2.6 Â 10 5 low-density lin À human fetal liver cells or the equivalent repopulating cells present in 10 7 unseparated lowdensity cells. The absolute output of terminally differentiating human myeloid (CD15/66b þ ) cells in the BM of the NOD/ SCID-3/GM/SF mice was slightly increased (B2-fold, Po0.05), but the number of CFU-GMs actually tended to be lower than in the regular NOD/SCID hosts. In contrast, human erythropoiesis in the BM of the NOD/SCID-3/GM/SF mice was significantly reduced (B10-fold fewer glycophorin A þ cells and B5-fold fewer CFU-E/BFU-Es, Po0.05).
The 6-week post-transplant BM content of human CD34 þ cells, like the CFC results, showed no significant difference between the two hosts ( Table 3 , P ¼ 0.1), although considerable variability between individual mice was again seen. The analysis of the more primitive subset of human CD34 þ CD38
À cells showed these to be slightly reduced (B1.5-fold) in the BM of the growth factor-producing mice, but the difference was not significant (P ¼ 0.3). However, when the number of human CD34 þ LTC-ICs was measured, a very pronounced reduction in their numbers was seen (116-fold, Po0.05). Representative FACS plots illustrating the increased frequency of human granulopoietic cells in the face of a decreased output of more primitive (CD34 þ CD38 À ) cells are shown in Figure 2 . We next asked whether this negative effect of continuous exposure to human IL-3/GM-CSF and SF on the regeneration in the BM of very primitive human cells would also be reflected at the level of cells with lymphomyeloid reconstituting activity. Accordingly, the BM cells were harvested from the four hind leg bones of both types of primary recipients transplanted 4-5 weeks previously with human fetal liver cells and limiting dilution assays of their repopulating activity were then performed in secondary NOD/SCID recipients. The results of these assays showed that there were no detectable NOD/SCID repopulating cells present in the BM of the primary transgenic NOD/SCID mice transplanted with human fetal liver cells, Table 2 Lack of effect of Epo injections on human erythropoiesis in the BM of NOD/SCID-3/GM/SF mice transplanted with normal adult human BM cells Values shown are the mean7s.e.m. of the number of human cells per mouse BM from three control mice and three +Epo mice assessed individually. These numbers were calculated as described in the Materials and methods section and Table 1 . whereas there was a two-fold net expansion in the number of these cells regenerated in the regular NOD/SCID mice (Table 4) . Thus, there was a marked decrease (of at least 18-fold) in the regeneration of repopulating cells in the BM of the human growth factor-producing mice.
Discussion
Understanding the long-term effects of growth factor manipulations of human hematopoietic cells in vivo is of considerable interest in view of the increasing clinical use of growth factor administration. In addition, a growing list of disease states have been associated with increased or inappropriate activation of hematopoietic growth factor production. [8] [9] [10] [11] 13 Studies of the impact of intermittent exposure of human hematopoietic cells to pharmacological doses of human growth factors injected repeatedly into engrafted immunodeficient mice have demonstrated significant stimulation of the numbers and types of progeny generated. 4, [25] [26] [27] [28] However, such experiments are expensive and time-consuming and do not recapitulate a state in which elevated levels of these growth factors are continuously sustained, as typically occurs when their production is endogenously activated.
An alternative approach is to create mice that constitutively produce human growth factors using transgenic technologies. Bock et al 29 reported results obtained in SCID mice also engineered to produce human IL-3, GM-CSF and SF demonstrating an increased frequency of growth factor-producing mice showing engraftment of human BM and cord blood cells detectable by reverse-transcriptase PCR analysis of human DNA. However, the SCID host is well known to be much less supportive of human hematopoietic cell engraftment than the NOD/SCID mouse, 26 and it is unclear how well the effects of human growth factors in SCID hosts can be extrapolated to NOD/SCID hosts. In the present studies, we used a transgenic line of NOD/SCID mice we have derived that produces serum levels of human IL-3, GM-CSF and SF in the 2-4 ng/ml range, and used these to determine the effects of these growth factors on a variety of parameters of murine and human hematopoiesis maintained under these conditions. In comparison to regular NOD/SCID hosts, an enhancement of terminal human granulopoiesis was seen in the BM. This finding is consistent with the well-described effects of human IL-3, GM-CSF and SF on human myeloid progenitors in vitro. 30 It also underscores the requirement of normal human myeloid progenitors differentiating in vivo for these (or related) growth factors to realize their full latent proliferative potential. A less expected result was the concomitant suppression of human erythropoiesis in the BM of the same growth factor-producing mice. Interestingly, this negative effect on terminal human erythroid cell output extended into the erythroid progenitor compartment, perhaps explaining why it was not reversed by repeated injections of Epo. Also unexpected was the finding of similar perturbations of the corresponding types of murine cells not thought previously to be responsive to these 'human-specific' growth factors. This latter finding points to the potential of low-affinity biochemical events leading to biologically significant changes when these are sufficiently frequent and/or continuous in an in vivo setting. However, in the present experimental model (NOD/SCID-3/ GM/SF mice), the perturbations in the output of murine hematopoietic cells at early stages of differentiation could still be controlled by endogenous mechanisms that regulate circulating WBC numbers, since these were not altered relative to regular NOD/SCID mice.
A second consequence of elevated levels of endogenously produced human IL-3, GM-CSF and SF was the increased numbers of progenitors found in the circulation. The mobilizing action of all three of these growth factors in human subjects is well known, 31 and evidence of human progenitor mobilization following administration of human G-CSF (7human SF) to mice engrafted with human G-CSF-mobilized peripheral blood CD34 þ cells has been reported previously. 5 Interestingly, the levels of human growth factors produced in these mice caused a mobilization of the murine progenitors in otherwise untreated mice, again reinforcing the ability of murine cells to respond directly to these factors and produce significant biological sequelae in vivo. It is thus not clear whether the mobilization of human progenitors seen in the NOD/SCID-3/GM/SF mice can be attributed exclusively to direct effects of the human factors they produce endogenously, or whether they are indirectly mediated via initial effects on murine cells. The molecular mechanisms leading to growth factor-induced progenitor mobilization are still not well delineated, although accumulating evidence suggests that they are complex and involve multiple cell types. 32 The transgenic NOD/SCID mouse line studied here may thus offer some unique features for the further dissection of this process as it pertains to human progenitors.
The third notable outcome of the present study was the observation of a marked reduction in the growth factorproducing mice of the most primitive types of human hematopoietic cells; that is, those characterized by a Table 4 Number of NOD/SCID repopulating cells regenerated in the BM of primary mice transplanted with human fetal liver cells 4 weeks previously 
CD34
þ CD38 À phenotype and functionally detected as LTC-ICs or cells capable of reconstituting human lymphomyelopoiesis in transplanted NOD/SCID mice. Specific quantification of the numbers of these cell types showed an increasingly negative effect on increasingly primitive cells. Thus in the transgenic NOD/SCID recipients of human fetal liver cells, no secondary repopulating cells were detected 6 weeks post-transplant, indicating a reduction in their regeneration of at least 18-fold. This suggests that the mechanism underlying this failure of primitive cell accumulation in the BM was due to a direct effect of their exposure to excessive levels of human IL-3, GM-CSF and SF causing an increased probability of their differentiation and premature extinction (exhaustion). Human IL-3, even in the presence of human SF, is less promoting of human LTC-IC expansion in vitro than other growth factor combinations 14 and, in cultures of murine cells, murine IL-3 (but not GM-CSF) has similar negative effects on the self-renewal of cells with lymphomyeloid differentiation potential. 33 However, it is quite likely that the permanently heightened exit of progenitors from the BM of the growth factor-producing NOD/SCID mice may also have contributed to the reduced numbers of primitive cells present.
Finally, it is interesting to note a number of parallels between the altered pattern of hematopoiesis seen in the NOD/SCID-3/ GM/SF mice engrafted with normal human cells and that seen in patients with CML. In both, a shift occurs in the BM in favor of myelopoiesis over erythropoiesis even when erythroid progenitors are present, and this is accompanied by a compromised ability of the LTC-ICs and repopulating cells to expand. A similar result is also obtained when primitive murine hematopoietic cells are engineered using retroviral vectors to overexpress murine IL-3, GM-CSF or G-CSF. [34] [35] [36] [37] In mice transplanted with such engineered cells, a lethal myeloproliferative syndrome is produced characterized by a deregulated production of myeloid cells, extramedullary hematopoiesis and an elevated output of myeloid cells in the blood. However, the syndrome is poorly transferred to secondary mice, suggesting a parallel deleterious effect on the engineered stem cells. Thus, long-term exposure of hematopoietic stem cells to growth factor conditions in vivo that do not favor their self-renewal may have significant pathological consequences highlighting the need for further studies to address this possibility.
